keyword
https://read.qxmd.com/read/36936936/case-report-clearance-of-longstanding-immune-deficiency-associated-vaccine-derived-polio-virus-infection-following-remdesivir-therapy-for-chronic-sars-cov-2-infection
#21
William Hywel Bermingham, Benjamin Canning, Thomas Wilton, Michael Kidd, Dimitra Klapsa, Manasi Majumdar, Kavitha Sooriyakumar, Javier Martin, Aarnoud P Huissoon
The global polio eradication campaign has had remarkable success in reducing wild-type poliovirus infection, largely built upon the live attenuated Sabin oral poliovirus vaccine. Whilst rare, vaccine poliovirus strains may cause infection and subsequently revert to a neurovirulent type, termed vaccine-derived poliovirus (VDPV). Persistent, vaccine derived infection may occur in an immunocompromised host (iVDPV), where it is a recognised complication following receipt of the Sabin vaccine. This has significant implications for the global polio eradication campaign and there is currently no agreed global strategy to manage such patients...
2023: Frontiers in Immunology
https://read.qxmd.com/read/36914610/separate-evaluation-of-fraction-absorbed-and-intestinal-availability-after-oral-administration-of-drugs-based-on-the-measurement-of-portal-and-systemic-plasma-concentrations-and-luminal-concentration
#22
JOURNAL ARTICLE
Yusuke Tanaka, Kazuhiro Ito, Takanori Kurakazu, Satoshi Kasaoka
There are several experimental methods to estimate the product of the fraction absorbed (Fa) and intestinal availability (Fg) in vivo after oral administration of drugs. Metabolic enzyme inhibitors are typically used to separate Fg from Fa·Fg. Since Fa·Fg can be regarded as Fa under metabolism-inhibited conditions, Fg can be isolated by dividing Fa·Fg by Fa. However, if the inhibition of intestinal metabolism is insufficient, Fa is overestimated, which results in an underestimation of Fg compared to the actual value...
March 13, 2023: Molecular Pharmaceutics
https://read.qxmd.com/read/36735880/a-mouse-model-and-pathogenesis-study-for-cva19-first-isolated-from-hand-foot-and-mouth-disease
#23
JOURNAL ARTICLE
Wangquan Ji, Ling Tao, Dong Li, Peiyu Zhu, Yuexia Wang, Yu Zhang, Liang Zhang, Shuaiyin Chen, Haiyan Yang, Yuefei Jin, Guangcai Duan
Abstract Coxsackievirus A19 (CVA19) is a member of Enterovirus (EV) C group in the Picornaviridae family. Recently, we reported a case of CVA19-infected hand, foot, and mouth disease (HFMD) for the first time. However, the current body of knowledge on the CVA19 infection, particularly the pathogenesis of encephalomyelitis and diarrhea is still very limited, due to the lack of suitable animal models. Here, we successfully established a CVA19 mouse model via oral route based on 7-day old ICR mice. Our results found the virus strain could directly infect the neurons, astrocytes of brain and motor neurons of spinal cord causing neurological complications, such as acute flaccid paralysis (AFP)...
February 3, 2023: Emerging Microbes & Infections
https://read.qxmd.com/read/36635905/hepatitis-e-virus-and-zoonosis-recent-advances-and-therapeutic-implications
#24
JOURNAL ARTICLE
Kam Lun Ellis Hon, Alexander K C Leung, Alex Wong, Siddharth Sridhar
BACKGROUND: Hepatitis E is viral hepatitis caused by infection with the hepatitis E virus (HEV). OBJECTIVE: This article aims to review HEV disease and recent advances in the management of hepatitis E. METHODS: We used PubMed Clinical Queries and keywords of "hepatitis E", "hepatitis E virus" AND "zoonosis" as the search engine. "Therapy", "Clinical Prediction Guides", "Diagnosis", "Etiology" and "Prognosis" were used as filters, and "Narrow" scope was used...
January 12, 2023: Recent advances in inflammation & allergy drug discovery
https://read.qxmd.com/read/36309363/safety-and-efficacy-of-direct-acting-antiviral-therapies-for-chronic-hcv-infection-in-hemodialysis-patients
#25
JOURNAL ARTICLE
Gabriela Droc, Mircea Istrate, Adriana Mercan-Stanciu, Mihai Dodot, Teodora Isac, Letitia Toma, Anca Zgura, Anca Trifan, Andreea Nicoleta Serbanica, Laura Iliescu, Laurentiu Micu
BACKGROUND/AIM: The aim of this study was to determine the safety and efficacy of a direct-acting antiviral treatment, ombitasvir/paritaprevir/ritonavir and dasabuvir, without ribavirin, in a real-life setting. PATIENTS AND METHODS: We performed a prospective observational study including 108 patients undergoing hemodialysis for end-stage kidney disease, referred to our clinic for antiviral therapy for chronic hepatitis C virus infection. Patients received treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, for 12 weeks...
2022: In Vivo
https://read.qxmd.com/read/36305304/final-results-from-the-ribavirin-pregnancy-registry-2004-2020
#26
JOURNAL ARTICLE
Susan M Sinclair, Judith K Jones, Richard K Miller, Michael F Greene, Paul Y Kwo, Willis C Maddrey
INTRODUCTION: Significant teratogenic effects have been demonstrated for ribavirin in animal studies. Ribavirin is prescribed for chronic hepatitis C and is contraindicated in pregnant women and their male sexual partners. Both are advised to avoid pregnancy for 6 months after exposure. The registry monitored pregnancy exposures to oral formulations of ribavirin for hepatitis C for signals of possible human teratogenicity from 2004 to 2020. METHODS: Pregnant women were voluntarily enrolled following direct exposure (ribavirin use during pregnancy or the 6 months prior) or indirect exposure (through sexual contact during pregnancy or 6 months prior, with a man who has taken ribavirin within 6 months)...
December 1, 2022: Birth Defects Research
https://read.qxmd.com/read/36284392/hand-foot-and-mouth-disease-a-narrative-review
#27
REVIEW
Alexander K C Leung, Joseph M Lam, Benjamin Barankin, Kin Fon Leong, Kam Lun Hon
BACKGROUND: Hand, foot, and mouth disease is a common viral disease in childhood. Because the disease has the potential to reach epidemic levels and mortality is high in some countries, early recognition of this disease is of paramount importance. OBJECTIVE: This purpose of this article is to familiarize pediatricians with the clinical manifestations and management of hand, foot, and mouth disease. METHODS: A search was conducted in February 2022 in PubMed Clinical Queries using the key term "hand, foot, and mouth disease"...
2022: Recent advances in inflammation & allergy drug discovery
https://read.qxmd.com/read/36275730/case-report-chronic-hepatitis-e-in-a-hematopoietic-stem-cell-transplant-recipient-the-first-report-of-hepatitis-e-virus-genotype-4-causing-chronic-infection-in-a-non-solid-organ-recipient
#28
Zihao Chen, Junfeng Wei, Li Jiang, Dong Ying, Weikun Tian, Mengyang Zhang, Guiping Wen, Siling Wang, Chang Liu, Yingbin Wang, Ting Wu, Zimin Tang, Zizheng Zheng, Li Yan, Ningshao Xia
Hepatitis E virus (HEV) is one of the most important public health issues around the world, and chronic HEV infection has been reported in immunosuppressed individuals. This study reported a male case, with very severe aplastic anemia (AA), who developed chronic hepatitis E after hematopoietic stem cell transplantation (HSCT). Abnormal alanine aminotransferase (ALT) appeared after HSCT and persisted for twenty-nine months. The case was seropositive for anti-HEV IgG and IgM after HSCT. Twenty-two months after HSCT, HEV RNA and antigen (Ag) testing were positive and persisted for five and seven months, respectively...
2022: Frontiers in Immunology
https://read.qxmd.com/read/36090063/cangma-huadu-granules-attenuate-h1n1-virus-induced-severe-lung-injury-correlated-with-repressed-apoptosis-and-altered-gut-microbiome
#29
JOURNAL ARTICLE
Mingjiang Liu, Tengwen Liu, Xuerui Wang, Chenglong Yu, Tao Qin, Jingui Li, Mina Zhang, Zhenxuan Li, Xuran Cui, Xiaolong Xu, Qingquan Liu
Severe influenza A virus infection leads to overwhelming inflammatory responses and cellular apoptosis, which causes lung injury and contributes to high mortality and morbidity. The gut microbiome altered in response to the infection might influence the disease progression and the treatment outcome. Cangma Huadu (CMHD) granules, an in-hospital preparation of traditional Chinese medicine, have been shown to be favorable in the clinical treatment of influenza. However, the effects and mechanisms of CMHD granules on severe influenza pneumonia and its mechanisms are not well-known...
2022: Frontiers in Microbiology
https://read.qxmd.com/read/36043559/severe-hepatitis-e-in-an-immunocompetent-young-woman-treated-with-ribavirin
#30
JOURNAL ARTICLE
Maria Azevedo Silva, André Ruge Gonçalves, Carina Leal, Liliana Eliseu
A healthy 24-year-old woman was admitted to the emergency department with acute hepatitis. She denied traveling, consumption of drugs, herbs, alcohol or medication other than the same oral contraceptive for years. The etiological work-up revealed positive Herpes Simplex Virus (HSV) 1+2 serology (IgG and IgM). Other viral serologies were negative, while Hepatitis E Virus (HEV) serology and viraemia were pending. Liver biopsy showed portal and lobular necroinflammatory activity without specific etiological findings...
August 31, 2022: Revista Española de Enfermedades Digestivas
https://read.qxmd.com/read/36016290/susceptibility-of-type-i-interferon-receptor-knock-out-mice-to-heartland-bandavirus-hrtv-infection-and-efficacy-of-favipiravir-and-ribavirin-in-the-treatment-of-the-mice-infected-with-hrtv
#31
JOURNAL ARTICLE
Hikaru Fujii, Hideki Tani, Kazutaka Egawa, Satoshi Taniguchi, Tomoki Yoshikawa, Shuetsu Fukushi, Souichi Yamada, Shizuko Harada, Takeshi Kurosu, Masayuki Shimojima, Takahiro Maeki, Chang-Kweng Lim, Mutsuyo Takayama-Ito, Takashi Komeno, Nozomi Nakajima, Yousuke Furuta, Akihiko Uda, Shigeru Morikawa, Masayuki Saijo
Heartland bandavirus (HRTV) is an emerging tick-borne virus that is distributed in the United States and that causes febrile illness with thrombocytopenia and leukocytopenia. It is genetically close to Dabie bandavirus, which is well known as severe fever with thrombocytopenia syndrome (SFTS) virus (SFTSV). The mortality rate of human HRTV infection is approximately 10%; however, neither approved anti-HRTV agents nor vaccines exist. An appropriate animal model should be developed to evaluate the efficacy of antiviral agents and vaccines against HRTV...
July 28, 2022: Viruses
https://read.qxmd.com/read/35909276/covid-19-pathophysiology-transmission-and-drug-development-for-therapeutic-treatment-and-vaccination-strategies
#32
JOURNAL ARTICLE
Vishal Kumar Singh, Himani Chaurasia, Richa Mishra, Ritika Srivastava, Aditya K Yadav, Jayati Dwivedi, Prashant Singh, Ramendra K Singh
COVID-19, a dreaded and highly contagious pandemic, is flagrantly known for its rapid prevalence across the world. Till date, none of the treatments are distinctly accessible for this life-threatening disease. Under the prevailing conditions of medical emergency, one creative strategy for the identification of novel and potential antiviral agents gaining momentum in research institutions and progressively being leveraged by pharmaceutical companies is target-based drug repositioning/repurposing. A continuous monitoring and recording of results offer an anticipation that this strategy may help to reveal new medications for viral infections...
July 29, 2022: Current Pharmaceutical Design
https://read.qxmd.com/read/35876973/ribavirin-for-treatment-of-subjects-with-respiratory-syncytial-virus-related-infection-a-systematic-review-and-meta-analysis
#33
REVIEW
Sofia Tejada, Raquel Martinez-Reviejo, Hanife N Karakoc, Yolanda Peña-López, Oriol Manuel, Jordi Rello
INTRODUCTION: Respiratory syncytial virus (RSV)-associated diseases have caused an estimated 1.8 million hospital admissions and 40,000 deaths among children. RSV can cause lower respiratory tract infections (LRTIs) in all age groups, adults with comorbidities, and immunocompromised patients. The aim was to summarize the evidence concerning efficacy and safety of ribavirin in subjects diagnosed with RSV associated with LRTI. METHODS: A systematic review and meta-analysis were performed...
September 2022: Advances in Therapy
https://read.qxmd.com/read/35538812/comparative-real-life-egyptian-experience-of-the-combination-of-sofosbuvir-plus-daclatasvir-or-simeprevir-for-12-weeks-in-na%C3%A3-ve-cirrhotic-patients-infected-with-hcv-genotype-4
#34
JOURNAL ARTICLE
Sayed Ahmed, Essam Hassan, Ahmed Gomaa, Gamal Esamat, Ahmed Ramadan, Manar Ahmed, Aya Elsayed, Engy A Wahsh
BACKGROUND: Chronic infection with HCV is a progressive worldwide health problem and the core reason for liver cirrhosis, portal hypertension, or hepatocellular carcinoma. HCV-G4 represents the most common threat for transplantation of the liver in Egypt. New interferon-free regimens have been started consuming direct-acting antiviral oral tablets for HCV cure. OBJECTIVES: In the current study, comparing the safety and efficacy of DAAs combination regimens including sofosbuvir with daclatasvir or sofosbuvir with simeprevir plus ribavirin for naïve cirrhotic Egyptian patients infected with HCV-G4 was our main goal...
May 10, 2022: Current Drug Safety
https://read.qxmd.com/read/35502409/does-hepatitis-c-virus-treatment-by-directly-acting-antivirals-obligate-shifting-patients-with-type-2-diabetes-from-oral-hypoglycemic-drugs-to-insulin-therapy
#35
JOURNAL ARTICLE
Rasha Youssef Hagag, Ahmed Fawzy Selim, Omneya Mohamed Darrag, Hassan Zied, Mohamed Sabry Aboelnasr
Purpose: The aim of the present work was to investigate whether hepatitis C virus treatment by directly acting antivirals obligate shifting patients with type 2 diabetes from oral hypoglycemic drugs to insulin therapy. Methods: This was a prospective study including 92 treatment-naïve patients with chronic hepatitis C virus infection and type 2 diabetes who were eligible for treatment with directly acting antivirals (sofosbuvir + daclatasvir ± ribavirin). Patients in the study were divided into two groups; group 1 included 22 patients on insulin therapy and group 2 included 70 patients on oral antidiabetic medications...
2022: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/35339025/pharmacodynamic-and-therapeutic-pilot-studies-of-single-agent-ribavirin-in-patients-with-human-papillomavirus-related-malignancies
#36
JOURNAL ARTICLE
Bharat Burman, Scott B Drutman, Matthew G Fury, Richard J Wong, Nora Katabi, Alan L Ho, David G Pfister
OBJECTIVES: Ribavirin inhibits eukaryotic translation initiation factor 4E (eIF4E), thereby decreasing cap-dependent translation. In this two-part study, we assessed the pharmacodynamic effects and therapeutic potential of ribavirin in human papillomavirus (HPV)-related malignancies. METHODS: In the pharmacodynamic study, ribavirin (400 mg BID for 14 days) was evaluated in 8 patients with HPV-positive localized oropharyngeal carcinoma with phosphorylated-eIF4E (p-eIF4E) ≥ 30%...
May 2022: Oral Oncology
https://read.qxmd.com/read/35126848/direct-acting-antivirals-for-chronic-hepatitis-c-treatment-the-experience-of-two-tertiary-university-centers-in-brazil
#37
JOURNAL ARTICLE
Mariana Sandoval Lourenço, Patricia Momoyo Y Zitelli, Marlone Cunha-Silva, Arthur Ivan N Oliveira, Cláudia P Oliveira, Tiago Sevá-Pereira, Flair José Carrilho, Mario G Pessoa, Daniel F Mazo
BACKGROUND: Hepatitis C virus (HCV) treatment has undergone major changes in recent years. Previous interferon-based therapies have been replaced by oral direct-acting antivirals (DAA) regimens, with high sustained virologic response (SVR) rates, and a lower incidence of adverse events (AEs). AIM: To evaluate the efficacy and safety of DAAs for HCV treatment in subjects from two tertiary university centers in Brazil. METHODS: This is a multicenter retrospective cohort study of 532 patients with chronic hepatitis C (CHC), undergoing treatment with interferon-free regimens from November 2015 to November 2019...
January 27, 2022: World Journal of Hepatology
https://read.qxmd.com/read/35119042/network-meta-analysis-of-heat-clearing-and-detoxifying-oral-liquid-of-chinese-medicines-in-treatment-of-children-s-hand-foot-mouth-disease-a-protocol-for-systematic-review-and-meta-analysis
#38
JOURNAL ARTICLE
Jiqin Tang, Gong Zhang, Jinxiao Xing, Ying Yu, Tao Han
BACKGROUND: Hand-foot-mouth is a viral infectious disease characterized by fever, hand foot rash and oral mucosal herpes caused by a variety of enteroviruses. It is often found in preschool children, and its immune system is not well developed, so it is very susceptible to infection by pathogens and epidemics, resulting in rapid progress of the disease. At present, the commonly used Chinese patent medicine oral liquid in our country has good clinical efficacy of antiviral, antibacterial, antiphlogistic and improving immunity, but there is no evidence to compare the clinical efficacy and safety of a variety of oral liquid of Chinese patent medicine...
February 4, 2022: Medicine (Baltimore)
https://read.qxmd.com/read/34991982/an-update-on-drugs-with-therapeutic-potential-for-sars-cov-2-covid-19-treatment
#39
REVIEW
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, Filip Machaj, Bartosz Szostak, Jarosław Przybyciński, Shahrokh Lorzadeh, Katarzyna Kotfis, Saeid Ghavami, Marek J Łos
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century with more than 257 million cases and over 5.17 million deaths reported worldwide (as of November 23, 2021. Various agents were initially proclaimed to be effective against SARS-CoV-2, the etiological agent of COVID-19. Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic agents, whose efficacy against COVID-19 was later disproved. Meanwhile, concentrated efforts of researchers and clinicians worldwide have led to the identification of novel therapeutic options to control the disease including PAXLOVID™ (PF-07321332)...
December 2021: Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
https://read.qxmd.com/read/34916812/ribavirin-treatment-for-critically-ill-covid-19-patients-an-observational-study
#40
JOURNAL ARTICLE
Yonghao Xu, Manshu Li, Liang Zhou, Dongdong Liu, Weiqun He, Weibo Liang, Qingwen Sun, Huadong Sun, Yimin Li, Xiaoqing Liu
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has spread all over the world resulting in high mortality, yet no specific antiviral treatment has been recommended. METHODS: A retrospective descriptive study was conducted involving 19 consecutive critically ill patients during January 27, 2020 to April 18, 2020. Ribavirin was given at 0.15g q8h orally upon ICU admission for 7 to 21 days. Here, 28-day mortality, lower respiratory tract specimens (ETA), and ribavirin side effect on the day of ICU admission (Day 1), Day 7, Day 14 and Day 21 were analyzed...
2021: Infection and Drug Resistance
keyword
keyword
89557
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.